First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. by Pier Paolo Piccaluga, Stefania Paolini, Clara Bertuzzi, Antonio De Leo, Gianantonio Rosti
© 2012 Piccaluga et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Blood Medicine 2012:3 151–156
Journal of Blood Medicine
First-line treatment of chronic myeloid leukemia 
with nilotinib: critical evaluation
Pier Paolo Piccaluga*
Stefania Paolini*
Clara Bertuzzi
Antonio De Leo
Gianantonio Rosti
Hematopathology and Hematology 
Sections, Department of Hematology 
and Oncological Sciences, “L and 
A Seràgnoli”, S Orsola-Malpighi 
Hospital, University of Bologna, 
Bologna, Italy
*These authors contributed equally  
to this work
Correspondence: Pier Paolo Piccaluga 
Molecular Pathology Laboratory, 
Hematopathology Section, Department 
of Hematology and Oncology, “L and  
A Seràgnoli”, S Orsola-Malpighi Hospital, 
University of Bologna, Via Massarenti, 
9-40138 Bologna, Italy 
Tel +39 05 1636 4043 
Fax +39 05 1636 4037 
Email pierpaolo.piccaluga@unibo.it
Abstract: The therapeutic landscape of chronic myeloid leukemia (CML) has changed 
dramatically in the last decade. In particular, the availability of imatinib mesylate, a tyrosine 
kinase inhibitor targeting BCR-ABL, has led to profound and durable remissions in the major-
ity of patients. However, a couple of issues have emerged and partially obscured this scenario. 
First, it has become clear that a significant proportion of patients either present with primary 
resistance to imatinib or develop secondary resistance sooner or later during treatment. Second, 
although the drug is generally well tolerated, a percentage of patients eventually cease treatment 
because of toxicity. Bearing this in mind, second-generation tyrosine kinase inhibitors have 
been introduced, including nilotinib. Phase I and II studies indicate remarkable activity for this 
compound in CML cases resistant to imatinib, including some of those carrying BCR-ABL1 
mutants. More recently, two Phase II studies and a III randomized Phase clinical trial demon-
strated the superiority of nilotinib compared with imatinib in terms of complete cytogenetic and 
major molecular responses, which are two relevant surrogate measures of long-term survival 
in CML. In this paper, we review the most relevant data on nilotinib as first-line treatment for 
CML, and discuss the rationale for its routine use, as well as some possible future perspectives 
for CML patients.
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Background
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized 
clinically by three distinct phases, ie, chronic, accelerated, and blastic, and occurs 
in 1.0–1.5 per 100,000 people each year in Western countries.1 Of note, CML is the 
prototype genetic cancer, presenting with the Philadelphia chromosome as a molecu-
lar hallmark. This is a truncated derivative of chromosome 22 that arises from the 
translocation of genetic material between this chromosome and -t(9;22)(q34;q11) 
on chromosome 9.2,3 The resulting fusion gene, BCR-ABL1 (breakpoint cluster 
region, Abelson murine leukemia viral proto-oncogene), encodes for an abnormal, 
nonmembrane-bound oncoprotein. This oncoprotein is a constitutively active tyrosine 
kinase that perturbs numerous signal transduction pathways, resulting in uncontrolled 
cell proliferation, reduced apoptosis, and impaired cell adhesion, and has been 
shown to induce transformation in vivo, determining CML and acute lymphoblastic 
leukemia-like syndromes in mice.4,5 Two fusion proteins of differing sizes may be 
produced, ie, p190 and p210, the latter being the one typically found in patients with 
CML.6 The oncoprotein BCR-ABL is associated with deregulated and increased ABL 
tyrosine kinase activity,7 demonstrating activation in multiple signal transduction 
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pathways, including Ras/Raf/mitogen-activated protein 
kinase,  phosphatidylinositol 3 kinase, STAT5/Janus kinase, 
and MYC.8 Many of these pathways are used by cytokines 
to regulate hematopoiesis, thereby allowing BCR-ABL to 
prolong survival and increase proliferation of cells in early 
leukemogenesis. BCR-ABL has also been shown to associ-
ate directly with some of the SRC family tyrosine kinases, 
including LYN and HCK, which facilitate BCR-ABL cou-
pling to pathways related to transformation.8–11
Because BCR-ABL tyrosine kinase activity is  necessary 
for tumor induction and maintenance, this relationship 
represented an ideal rationale for developing small mol-
ecule tyrosine kinase inhibitors.12 Remarkably, this led to 
the approval of the first molecularly targeted drug in 2000, 
ie, imatinib mesylate (Glivec®, Novartis Pharma, Basel, 
 Switzerland), which dramatically changed the clinical 
 scenario for CML.13 Before introduction of imatinib, effec-
tive treatment for CML was limited to a minority of patients. 
In particular, interferon-alpha (IFNα)-based regimens were 
shown to improve disease-free and overall survival signifi-
cantly compared with hydroxyurea, with durable responses 
induced in 10%–30% of patients.14–16 However, this benefit 
was mostly limited to patients with a low Sokal score and 
was hampered by significant toxicity. In addition, allogeneic 
hematopoietic stem cell transplant in the first chronic phase 
could cure around half of the patients, transplant-related 
mortality and morbidity were considerable, and many patients 
were not eligible due to age, comorbidities, or lack of a 
suitable donor.17,18 On the other hand, it was demonstrated 
in IRIS (International Randomized study of Interferon/IFN 
versus STI571) that five-year survival in patients diagnosed 
with CML in the chronic phase improved from approximately 
50% with previous IFN-based regimens to approximately 
90% with imatinib.19,20 Of note, IRIS also recognized com-
plete cytogenetic responses and major molecular responses, 
defined as a 3-log reduction in BCR-ABL transcripts com-
pared with a standardized baseline, as key achievements 
associated with remarkable long-term outcome, and provided 
a rationale for using these surrogate endpoints in subse-
quent clinical trials.18,20–22 Of note, this strategy was recently 
accepted by the European LeukemiaNet and proposed in a 
consensus guideline21,23 (Table 1).
Despite these excellent results, some concerns emerged 
regarding the actual impact of imatinib therapy. First, it 
turned out that a substantial fraction of the IRIS patients 
had left the study, and for a variety of reasons.18,19 In fact, 
at a follow-up of eight years, only 55% of patients initially 
treated with imatinib were still receiving the drug, while the 
Table 1 Definition of response to imatinib in chronic phase 
chronic myeloid leukemia*
Evaluation  
time
Response
Optimal Suboptimal Failure
3 months CHR and at least  
minor CyR
No CyR No CHR
6 months At least  
partial CyR
Less than  
partial CyR
No CyR
12 months CCyR Partial CyR Less than  
partial CyR
18 months MMR Less than  
partial MMR
Less than  
CCyR
Any time Stable or  
improving MMR
Loss of MMR,  
presence of  
mutations
Loss of CHR,  
loss of CCyR,  
clonal evolution
Note: *European LeukemiaNet guidelines.
Abbreviations: CHR, complete hematologic response; CCyR, complete cytogenetic 
response; CyR, cytogenetic response; MMR, major molecular response.
remainder had discontinued therapy, mostly because of an 
unsatisfactory therapeutic effect or toxicity.18,24 Subsequent 
studies consistently indicated that the clinical outcome with 
imatinib was significantly less favorable in the community 
setting. In this regard, a study conducted in the UK showed 
an event-free survival of only 63% at 5 years.25 In addition, 
a French group showed that only half of patients had a 
complete cytogenetic response and were still on treatment at 
24 months in a population-based study of CML patients.26
Furthermore, resistance to imatinib has emerged as a 
significant clinical issue. Leukemic cells can develop vari-
ous mechanisms of resistance during therapy.  Specifically, 
primary resistance is defined as failure to achieve a complete 
remission despite therapeutic levels of imatinib, whereas 
secondary or acquired resistance to imatinib arises in the 
form of a relapse after an initial complete remission has 
been obtained. Several mechanisms of drug resistance 
have been postulated, including: expression of a rapid drug 
efflux protein; extracellular binding of drug molecules; 
non-BCR-ABL-dependent transforming events; and BCR-
ABL- dependent events involving genetic changes in the 
ATP binding site that lead to decreased binding affinity for 
imatinib. Genetic mutations in BCR-ABL result in several 
possible changes, ie, overexpression of BCR-ABL, disruption 
of contact points between imatinib and BCR-ABL, and/or 
structural changes that activate BCR-ABL, thereby prevent-
ing the inhibitor from binding.10,27–30
Therefore, novel second-generation tyrosine kinase inhib-
itors, including dasatinib (Sprycel®, Bristol-Meyer-Squibb, 
New York, NY) and nilotinib (formerly AMN107, Tasigna®, 
Novartis Pharma, Basel, CH), have been developed and 
introduced since 2007. In this paper, we review the available 
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data on use of nilotinib as first line-treatment based on our 
own experience as well as on the literature, and discuss the 
future perspectives for patients with CML.
Nilotinib as front-line treatment  
for CML
Nilotinib is a highly potent BCR-ABL inhibitor that was 
initially approved for the treatment of patients who have 
failed prior therapy, including imatinib. Notably, it is active 
against most imatinib-resistant mutations of BCR-ABL 
(except T315I) and induces durable cytogenetic responses 
in approximately 50% of patients in chronic phase when 
used as second-line therapy,31,32 but responses in patients in 
advanced phase tend to be transient. Importantly, nilotinib 
has been recently compared with imatinib in the front-line 
chronic phase setting.
Initially, the Gruppo Italiano Malattie EMatologiche 
dell’Adulto (GIMEMA) enrolled 73 patients in a 
Phase II trial, where patients received nilotinib at a dose 
of 400 mg twice daily and were followed up for a mean of 
30 months. This study confirmed the remarkable efficacy 
of nilotinib, with complete cytogenetic response, major 
molecular response, and complete molecular response 
rates at 24 months of 96%, 85%, and 12%, respectively. 
Only four patients (5%) discontinued nilotinib because of 
toxicity33 (Table 2).
Subsequently, a study carried out in the US at the MD 
Anderson Cancer Center evaluated 51 patients with newly 
diagnosed CML in chronic phase treated with nilotinib 400 mg 
twice daily in the front-line setting.34 At 24 months, 93% of 
patients achieved a complete cytogenetic response and 79% 
had a major molecular response (Table 2). Notably, the pro-
jected event-free survival was 90% at 24 months. Treatment 
was well tolerated, the most frequent grade 3/4 adverse events 
being neutropenia (12%) and thrombocytopenia (11%). 
Accordingly, at 12 months, the median dose received was 
800 mg, as initially scheduled. Overall, this study indicated 
that nilotinib is an effective option for front-line treatment 
of CML patients in chronic phase.34
Finally, the Phase III randomized ENESTnd  (Evaluating 
Nilotinib Efficacy and Safety in Clinical Trials Newly 
Diagnosed Philadelphia Chromosome Positive) trial com-
pared imatinib 400 mg twice daily with nilotinib 300 mg or 
400 mg twice daily as first-line therapy in patients with CML 
in early chronic phase.35,36 At 12 months, major molecular 
response rates for nilotinib (44% for the 300 mg dose and 
43% for the 400 mg dose) were significantly superior to that 
for imatinib (22%, P , 0.001).35 In addition, on extended 
follow-up at 24 months, the survival analyses indicated 
nilotinib 300 mg twice daily as the optimal treatment arm. 
In particular, compared with imatinib, nilotinib 300 mg 
twice daily resulted in superior progression-free survival 
(98% versus 95.2%; P = 0.0437), and improved complete 
cytogenetic response and major molecular response rates at 
24 months (87% versus 77%, P = 0.0018, and 71% versus 
44%, P = 0.0001,  respectively). In addition, a significant 
lower rate of progression to accelerated/blastic phases was 
recorded in the nilotinib arms. The more frequent side effects 
were skin rash, myalgia, and increases in bilirubin, lipase and 
blood glucose on nilotinib, and fatigue, myalgia, and fluid 
retention on imatinib.35,36
Based on these results, nilotinib was approved as front-
line therapy for newly diagnosed patients in the US and in 
some countries in the European Union. Of note, the gap 
in efficacy in favor of nilotinib has persisted over time, 
and it appears that nilotinib may improve both short-term 
(12 months) and long-term ($24 months) outcomes com-
pared with imatinib (Tables 2 and 3).
Resistance to nilotinib: beyond 
second-generation tyrosine kinase 
inhibitors
Although nilotinib and other approved second-generation 
tyrosine kinase inhibitors (eg, dasatinib, which is not dis-
cussed in this review),37 achieve a significantly improved 
outcome in the vast majority of patients with CML in chronic 
phase (CML-CP), a few patients with CML-CP and those 
with disease in advanced phase still present with primary 
Table 2 Response rates with nilotinib as first-line treatment for chronic myeloid leukemia in chronic phase
Clinical phase Patients (n) Dose¥ CCyR (%) MMR (%) Reference
II 73 400 mg¥ 96* 85* Rosti et al33
II 51 400 mg¥ 93* 79* Cortes et al34
III 846 300 mg (nilotinib)¥ (n = 282) 80§ (87)* 44§ (71)* Saglio et al35,§
400 mg (nilotinib)¥ (n = 281) 78§ (85)* 43§ (67)* Hagop et al36,*
400 mg (imatinib) (n = 283) 65§ (77)* 22§ (44)*
Notes: ¥Twice daily; *24 months; §12 months.
Abbreviations: CCyR, complete cytogenetic response; MMR, major molecular response.
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or secondary resistance. Because BCR-ABL1 mutations are 
common causes of resistance, much effort have been made 
to identify compounds able to overcome this phenomenon. 
In this regard, ponatinib (formerly AP24534), a multitargeted 
kinase inhibitor, was shown experimentally to be active 
against all tested BCR-ABL mutants, including T315I, 
in vitro.38 In a Phase I study including mostly patients who 
had previously failed at least two tyrosine kinase inhibitors, 
more than 50% of cases with CML-CP achieved a complete 
cytogenetic response.39 Of interest, the complete response rate 
was remarkably high (close to 100%) in patients carrying the 
T315I mutation, apparently (and paradoxically) abrogating 
the prognostically unfavorable effect of this biomarker.18,39 
Conversely, as expected, the response rate was lower in 
patients with advanced disease.
On the other hand, emerging evidence supports the 
concept that tyrosine kinase inhibitor resistance is largely 
mediated by mechanisms different from tyrosine kinase 
domain mutations. In fact, many patients with resistance, 
particularly primary resistance, do not have BCR-ABL1 
kinase domain mutations.10,18,40,41 In addition, with the 
exception of the pan-resistant T315I mutant, there is only a 
partial correlation between in vitro sensitivity and in vivo 
response, suggesting the contribution of other mechanisms, 
including ones that are independent of BCR-ABL,42,43 as 
described above. Therefore, treatment of patients with 
suboptimal response to second-generation tyrosine kinase 
inhibitors might include agents such as histone deacetylase 
inhibitors, aurora kinase and Hedgehog pathway inhibitors, 
omacetaxine, and a combination of tyrosine kinase inhibitors 
with newer or older compounds, eg, IFNα.44 Finally, until 
novel drugs and combinations emerge as effective strategies 
in resistant cases, stem cell transplantation should be always 
considered when a suitable donor is available.
Perspectives
In light of the aforementioned studies, it is difficult to 
conclude that every patient with CML should receive front-
line treatment with nilotinib or another second-generation 
tyrosine kinase inhibitor. In favor of this hypothesis is the 
close association between complete cytogenetic response/
major molecular response and clinical outcome already 
documented with imatinib, as well as the logic of minimiz-
ing the risk of disease progression by reducing the leukemia 
burden more rapidly and profoundly.18 Further, possible dif-
ferences in the molecular mechanism of the two drugs may 
support use of nilotinib. In this regard, it was recently shown 
that imatinib and nilotinib may exert opposite effects on 
telomere biology and, paradoxically, on cell proliferation.45 
In particular, inhibition of BCR-ABL by low-dose imatinib 
has the potential for indirect induction of telomerase activity 
through regulation of telomeric-associated proteins, namely, 
overexpression of tankyrase and downregulation of telomeric 
repeat binding factor 1 interacting nuclear factor 2.46 This 
leads to lengthening of telomeres and paradoxical enhance-
ment of cell proliferation. Conversely, nilotinib shows 
inhibitory activity against telomerases, leading to arrest of 
proliferation.45 On the other hand, significant differences 
in overall survival have yet to be observed with nilotinib 
(or dasatinib), with longer follow-up being needed. Event-
free survival is excellent in patients with a low Sokal risk 
score when imatinib is used, suggesting that these patients 
Table 3 Response rates with nilotinib or imatinib in the ENESTnd trial
Nilotinib 300 mg BID 
% of patients  
(n = 282)
Nilotinib 400 mg BID  
% of patients  
(n = 281)
Imatinib 400 mg QD  
% of patients  
(n = 283)
P value 
(nilotinib arms  
versus imatinib)
CCyR by 12 months 80 78 65 ,0.001–0.001
 High Sokal risk score 74 63 49  
CCyR by 24 months 87 85 77 0.0018–0.0016
MMR at 12 months 44 43 22 ,0.0001–0.0001
 Low Sokal risk score 41 53 26
 Intermediate Sokal risk score 51 40 23
 High Sokal risk score 41 32 17  
MMR at 24 months 62 59 37 ,0.0001/0.0001
CMR (any time) 26 21 10 –
Overall survival (%) 97.4 97.8 96.4
Progression-free survival (%) 98 97.7 95.2
Discontinued treatment (%) 26 22 33 –
Notes: Adapted from Lancet Oncol, 12, Kantarjian HM, Hochhaus A, Saglio G, et al, Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, 
Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial, 841–851, Copyright 2011, with permission 
from Elsevier36 and Saglio G, Kim Dw, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–2259.35
Abbreviations: ENESTnd, Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Philadelphia Chromosome Positive; BID, twice daily; QD, once daily; 
CCyR, complete cytogenetic response; MMR, major molecular response; CMR, complete molecular response.
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may be managed safely even with a less expensive drug, an 
issue that will become even more important in the few years 
after generic imatinib becomes available.18 Therefore, it is 
mandatory to improve our ability to predict outcomes in our 
patients using ad hoc molecular tests, eg, DNA sequencing 
and gene expression profiling, in order to offer the optimal 
strategy to individual patients.
Conclusion
Recent Phase II and III clinical trials have provided strong evi-
dence for the efficacy and tolerability of nilotinib as first-line 
treatment for patients with CML, especially those in chronic 
phase. The faster and more profound therapeutic effects of 
nilotinib, when compared with imatinib, suggest the possibility 
of longer event-free and overall survival, as well as a higher 
number of cured patients. On the other hand, actual long-term 
efficacy data are still lacking, and pharmacoeconomic concerns 
have emerged in Western countries in the light of the number of 
expensive new drugs approved in the last few years and escalat-
ing global expenditure by health care systems. Therefore, accu-
rate clinicobiological evaluation, an evidence-based approach, 
and identification of potential biomarkers are definitely war-
ranted to delineate the best approach in a given case.
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